Clinical characterization of patients with cervical cancer at the Provincial Gynecological-Obstetrical Hospital. Matanzas, 2023-2025
Keywords:
Cervical Cancer; Risk Factors; Prevention; Neoplasm Staging; CubaAbstract
Introduction: Cervical cancer (CC) is one of the leading causes of female mortality worldwide, with a high incidence in developing countries. In Cuba, it represents a significant health problem.
Objective: To characterize patients diagnosed with CC treated at the "José Ramón López Tabrane" Provincial Teaching Gynecological and Obstetrical Hospital in Matanzas between January 2023 and December 2025.
Methods: Observational, descriptive, cross‑sectional study. Eighty‑eight patients with histopathologically confirmed diagnosis were included. Sociodemographic variables, risk factors, obstetric history, sexual behavior, clinical stage, histological type, and screening history were analyzed. Descriptive statistics and chi‑square tests were used to explore associations.
Results: The predominant age group was 36‑40 years (28.4%), housewives (52.3%), single (61.4%), pre‑university education (56.8%), smokers (58.0%), Black (44.3%), and multiparous (43.2%). Sexual debut between 14‑19 years occurred in 60.2% and 3‑4 partners in 40.9%. Squamous cell carcinoma was the most frequent (67.0%) and stage II the predominant (38.6%). 67.0% had no screening in the last 3 years. Smoking (p=0.041) and multiparity (p=0.032) were significantly associated with more advanced stages.
Conclusions: The patient profile matches classical risk factors. The association between smoking, multiparity, and advanced stages, together with low screening coverage, reinforces the need to strengthen screening and preventive interventions in the province.
Downloads
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209 49. doi:10.3322/caac.21660
2. Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197-e206. doi:10.1016/S2214-109X(22)00501-0
3. Liu Y, Ai H. Comprehensive insights into human papillomavirus and cervical cancer: Pathophysiology, screening, and vaccination strategies. Biochim Biophys Acta Rev Cancer. 2024;1879(6):189192. doi:10.1016/j.bbcan.2024.189192
4. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; [Internet] 2020 [citado 24/11/2025]. Disponible en: https://www.who.int/publications/i/item/9789240014107
5. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case control study. Lancet. 2002;359(9312):1093 101. doi:10.1016/S0140-6736(02)08151-5
6. Ministerio de Salud Pública (MINSAP). Anuario Estadístico de Salud 2024. La Habana: MINSAP; [Internet] 2025 [citado 24/11/2025]. Disponible en: https://files.sld.cu/bvscuba/files/2025/05/Anuario-Estadistico-de-Salud-2024.pdf
7. Figueredo Fonseca M, Fernández Núñez D, Hidalgo Rodríguez M, Rodríguez Reúna R, Álvarez Paneque T. Intervención educativa sobre cáncer cervicouterino. Multimed. [Internet] 2021 [citado 24/11/2025];23(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1028-48182019000400731
8. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):28 44. doi:10.1002/ijgo.13865
9. Hermida Lazcano I. Caracterización de mujeres con diagnóstico de cáncer cervicouterino. Rev Cuba Obstet Ginecol. [Internet] 2021 [citado 24/11/2025];47(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-600X2021000200007
10. Palma Osorio M, Romero Flores AD, Torres Mesa AI. Factores de riesgo en las lesiones intraepiteliales del cuello uterino. Rev Finlay. [Internet] 2019 [citado 24/11/2025];9(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2221-24342019000400291
11. Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008;110(3 Suppl 2):S4 7. doi:10.1016/j.ygyno.2008.07.045
12. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26(Suppl 10):K29 41. doi:10.1016/j.vaccine.2008.06.019
13. Bravo Polanco E, Águila Rodríguez N, Guerra Villarpanda D, Blanco Vázquez Y, Rodríguez González O, Oliva Santana M. Cáncer cérvico uterino: prevención y tratamiento. Medisur. [Internet] 2020 [citado 24/11/2025];18(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1727-897X2020000400685
14. Akinyemiju TF. Socio economic and health access determinants of breast and cervical cancer screening in low income countries: analysis of the World Health Survey. PLoS One. 2012;7(11):e48834. doi:10.1371/journal.pone.0048834
15. Wang X, Ji Y, Liu J, Li X, Jiang J. Marital status and the risk of cervical cancer: a systematic review and meta analysis. Medicine (Baltimore). 2020;99(51):e23554. doi:10.1097/MD.0000000000023554
16. Matos Bisset A, Ali Pérez NA, Padrón Castillo M, Matos Bayeau AA, Cuevas Ramos B. Eficacia de la intervención educativa sobre el conocimiento del cáncer cérvicouterino. Acta Méd Centro [Internet]. 2019 [citado 24/11/2025];13(4):552-61. Disponible en: https://revactamedicacentro.sld.cu/index.php/amc/article/view/987
17. Díaz Brito Y, Báez Pupo MM, Pérez Rivero JL, García Placeres M. Presencia de algunos factores de riesgo de cáncer de cérvix en mujeres con citologías normales. Rev Cub Med Gen Integr. [Internet] 2014 [citado 24/11/2025];30(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252014000200005
18. Fernández Milán AM. Tabaquismo y su relación con otros factores de riesgo aterogénico en mujeres de edad mediana. Rev Cubana Med. [Internet] 2021 [citado 24/11/2025];60(2):1-9. Disponible en: https://www.medigraphic.com/pdfs/revcubmed/cm-2021/cm212f.pdf
19. Hecht SS, Hatsukami DK. Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention. Nat Rev Cancer. 2022;22(3):143-155. doi:10.1038/s41568-021-00423-4
20. Applebaum KM, Furniss CS, Zeka A, Posner MR, Smith JF, Bryan J, et al. Lack of association of alcohol and tobacco with HPV16 associated head and neck cancer. J Natl Cancer Inst. 2007;99(23):1801 10. doi:10.1093/jnci/djm234
21. Clarke MA, Devesa SS, Hammer A, Wentzensen N. Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA Oncol. 2022;8(6):895-903. doi:10.1001/jamaoncol.2022.0009
22. Gopalani SV, Sawaya GF, Rositch AF, et al. The impact of adjusting for hysterectomy prevalence on cervical cancer incidence rates and trends among women aged 30 years or older-United States, 2001-2019. Am J Epidemiol. 2024;193(8):1097-1105. doi:10.1093/aje/kwae041
23. Chacón Estrada L, Robert Brady Y, Martínez Casanova M. Desigualdades por condición racial en el complejo Osha-Ifá de Sagua la Grande. Ch [Internet]. 2024 [citado 24/11/2025];(25):176-95. Available from: https://chakinan.unach.edu.ec/index.php/chakinan/article/view/1161
24. Tamayo Lien TG, Varona Sánchez J, Borrego López J, Areces Delgado G. Relación colpohistológica en lesiones de cuello de alto grado. Rev Cubana Obstet Ginecol. [Internet] 2010 [citado 24/11/2025]; 36(3). Disponible en: http://scielo.sld.cu/pdf/gin/v36n3/gin12310.pdf
25. Hewavisenti RV, Arena J, Ahlenstiel CL, Sasson SC. Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk. Front Immunol. 2023;14:1112513. doi:10.3389/fimmu.2023.1112513
26. Jensen KE, Schmiedel S, Frederiksen K, Norrild B, Iftner T, Kjær SK. Risk for cervical intraepithelial neoplasia grade 3 or worse in relation to parity among women with persistent human papillomavirus infection: a cohort study. Cancer Epidemiol Biomarkers Prev. 2012;21(11):1949 55. doi:10.1158/1055-9965.EPI-12-0434
27. Oyouni AAA. Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines. J Infect Public Health. 2023;16(4):626-631. doi:10.1016/j.jiph.2023.02.014
28. Nelson CW, Mirabello L. Human papillomavirus genomics: Understanding carcinogenicity. Tumour Virus Res. 2023;15:200258. doi:10.1016/j.tvr.2023.200258.
29. Harper DM, Navarro-Alonso JA, Bosch FX, et al. Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review. Hum Vaccin Immunother. 2025;21(1):2497608. doi:10.1080/21645515.2025.2497608
30. Henschke N, Bergman H, Buckley BS, et al. Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination. Cochrane Database Syst Rev. 2025;11(11):CD015363. doi:10.1002/14651858.CD015363.pub2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Lisbet González-Díaz , Sandra García-González , Gonzalo González-Rodríguez , Adrián Hernández-La Rosa , José Luis Homma-Casto , Silvia Rendon-García
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Those authors who have publications with this journal accept the following terms: The authors will retain their copyright and guarantee the journal the right of first publication of their work, which will be simultaneously subject to the Recognition License. Creative Commons that allows third parties to share the work as long as its author and its first publication in this magazine are indicated. Authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a monographic volume) as long as the initial publication in this journal is indicated. Authors are allowed and recommended to disseminate their work through the Internet (e.g.: in institutional telematic archives or on your website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work.
